How effective is Apremilast after taking it for 3 months? Patient treatment feedback

Apremilast is an oral small molecule phosphodiesterase 4 (PDE4) inhibitor, mainly used to treat immune-mediated diseases such as psoriasis and psoriatic arthritis. As an immunomodulatory drug, it relieves skin lesions and joint symptoms by inhibiting the release of inflammatory factors such as TNF-α, IL-17 and IL-23. Usually patients can gradually see the effects within 4 to 12 weeks after taking the medicine, so taking 3 months is the key node to evaluate the treatment response.

According to clinical studies and patient feedback, more than half of patients with moderate to severe psoriasis have significantly reduced symptoms of skin erythema, scales and itching after taking Apremilast for 3 months, and some patients' PASI scores (Psoriasis Area and Severity Index) have dropped by more than 50%. Especially for patients who are not suitable for the use of biological agents or traditional immunosuppressants, Apremilast is particularly practical as a convenient option that does not require injections and can be taken orally.

Many patients mentioned in their treatment feedback that in addition to improving skin symptoms, Apremilast also has a certain effect in relieving joint pain and stiffness caused by psoriatic arthritis. Some patients report that morning stiffness is shortened, joint flexibility is improved, and daily activities are less affected. In addition, due to its non-immunosuppressive nature and relatively mild side effects, many patients say they can tolerate this treatment method well.

However, there are some patients who do not have satisfactory results after taking it for 3 months. They may only experience slight improvement, or even experience side effects such as loss of appetite, weight loss, and mild diarrhea. Generally speaking, Apremilast is well tolerated, and its efficacy varies depending on individual differences. It is recommended that patients return for a follow-up visit after taking the drug for 3 months, and the doctor will comprehensively evaluate whether to continue the current treatment or adjust the plan.

Reference materials:https://go.drugbank.com/drugs/DB05676